Stratec stock gains on improved quarterly figures and Xetra momentum

Stratec stock (ISIN DE000STRA555) is trading around 21.50 EUR on Xetra as of September 3, 2026, after recently marking a new six-month high at 25.40 EUR on September 1, 2026 according to market data from boerse.de and FinanzNachrichten.

Second quarter 2026 shows a turnaround

The Baden-Baden based diagnostics specialist Stratec SE reported earnings for the second quarter and first half of 2026, with revenue for the first six months down 5.1 percent to 112.53 million EUR compared with the prior year period according to an analysis cited by FinanzNachrichten.

At the same time, the second quarter alone showed a positive trend, with revenue rising 1.5 percent year on year, signaling that the company is gradually stabilizing after the weaker first quarter of 2026 as noted in the same first-half commentary.

According to the overview on Marketscreener, Stratec SE reported its results for the second quarter and six months ended June 30, 2026 on August 14, 2026, confirming that these figures represent the most recent interim report for the group.

Analyst view and guidance context

Market data compiled by Marketscreener indicate that consensus expectations see Stratec SE generating revenue of about 265 million EUR for fiscal year 2026 and 307 million EUR for 2027, while a previous year figure of 249 million EUR illustrates the growth path implied by these estimates.

In a recent analyst comment referenced by both Marketscreener and FinanzNachrichten, Deutsche Bank Research maintained its Hold rating on Stratec with a price target of 21 EUR, arguing that the latest quarterly numbers showed the expected improvement versus the first quarter of 2026.

This assessment places the current Xetra price level of around 21.50 EUR slightly above the analyst target, suggesting that the market is already pricing in a moderate continuation of the second quarter recovery and the guided 2026 revenue growth trajectory.

Stratec platforms in laboratory diagnostics

Stratec SE is known for developing and manufacturing fully automated analyzer systems and smart consumables that are used by global diagnostics players in fields such as immunoassays, molecular diagnostics and clinical chemistry.

These platform solutions are typically supplied on an original equipment manufacturer basis, meaning that Stratec builds instruments and cartridges which partners then brand and distribute under their own names, creating recurring revenue through long-term service and consumables contracts.

Stratec stock on Xetra and market metrics

On Xetra, the Stratec stock trades under the ticker SBS, with recent intraday data from FinanzNachrichten showing executed trades between 21.40 EUR and 21.75 EUR on September 2, 2026, and a volume of more than 1,000 shares at levels around 21.50 EUR during the afternoon.

According to the same Xetra order book overview, the current market capitalization derived from the trading price and shares outstanding stands in the low to mid hundreds of millions of EUR, positioning Stratec SE firmly in the German small to mid cap segment alongside other TecDAX and SDAX level companies, even though Stratec itself is listed outside the major DAX family indices.